The inauguration of a global pharmaceutical R&D facility in Ahmedabad, India, has been announced by Baxter Pharmaceuticals India Pvt. Ltd. The centre will accelerate innovation in the field of generic and specialty injectable medications, furthering the company’s purpose of saving and maintaining lives.
Alok Sonig, president of pharmaceuticals at Baxter International Inc., officially opened the R&D Center. In Ahmedabad, he was joined by Dr. Mahesh Chaubal, vice president of pharmaceuticals research and development at Baxter International Inc., and Dr. Sanju Dhawan, director of research at Baxter Pharmaceuticals India Pvt.
Commenting on the occasion, Alok Sonig said, “Our world-class Ahmedabad R&D Centre is critical to unleashing the full power of our pharmaceuticals pipeline and helping us advance patient care worldwide through differentiated injectable products to be commercialized globally.”
“The Covid-19 pandemic has further highlighted the critical importance of increasing access to healthcare and providing affordable, quality medicines. Our team in India, particularly those working in the Ahmedabad pharmaceuticals R&D Centre, will play an integral role in advancing our pipeline, expanding our products to new markets and innovating to continue responding to the needs of patients all over the world,” said Dr. Mahesh Chaubal.
